The Only Specialized Global Intellectual Property News Agency
A Member of Talal Abu-Ghazaleh Organization

banner

Cephalon Granted Temporary Restraining Order in AMRIX® Patent Litigation

23-May-2011 | Source : AG-IP News | Visits : 5461

FRAZER, Pa. - The United States District Court for the District of Delaware granted a motion filed by plaintiffs Cephalon Inc. and Eurand Inc., for a Temporary Restraining Order (TRO) enjoining Mylan Pharmaceuticals Inc., and Mylan Inc., from manufacturing, using, offering to sell or selling its cyclobenzaprine hydrochloride extended-release capsules, a generic version of Cephalon's branded product AMRIX®. A press release by Cephalon stated that the TRO remains in effect pending appeal.

"We are very pleased with the Court's decision to grant our request for a TRO," said Jerry Pappert, Executive Vice President and General Counsel for Cephalon. "We remain confident in the strength of the patents protecting AMRIX®, and believe we have a strong case on appeal."

Cephalon is a global biopharmaceutical company dedicated to discovering, developing and bringing to market medications to improve the quality of life of individuals around the world.

share



Related Articles